Fig. 4From: Kinetics of adaptive immune responses after administering mRNA-Based COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infectionsNeutralizing activity in individuals with or without prior SARS-CoV-2 infections. (a) representing neutralizing activity against the Wuhan strain, (b) against the Delta variant, and (c) against the Omicron variant. The upper panel represents the plaque reduction from each serum dilution. The lower panel demonstrates the PRNT50 titerBack to article page